Standout Papers

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia 2016 2026 2019 2022 844
  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia (2016)
    Hagop M. Kantarjian, Daniel J. DeAngelo et al. New England Journal of Medicine

Citation Impact

3 by Nobel laureates 4 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Natural killer cell therapies
2024 StandoutNature
2 intermediate papers

Works of Barbara Sleight being referenced

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016 Standout

Author Peers

Author PHEOH Oncology Hematology Last Decade Papers Cites
Barbara Sleight 855 851 601 23 1.4k
Petros M. Pavlopoulos 3 125 50 28 638
Guy Gilron 1 1 20 384
Shen Li Zhang 2 53 2 2 135
Li Ma 2 8 4 11 257
Ari Karchin 8 6 36 9 354

All Works

Loading papers...

Rankless by CCL
2026